We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
GlaxoSmithKline (GSK) is set to produce one billion doses of its pandemic vaccine adjuvant system next year to support adjuvanted Covid-19 vaccine candidates development.